Last reviewed · How we verify

IV acetaminophen & IV dexmedetomidine

Beth Israel Deaconess Medical Center · FDA-approved active Small molecule

This combination uses acetaminophen to reduce pain and fever via COX inhibition, and dexmedetomidine to provide sedation and analgesia through alpha-2 adrenergic receptor agonism.

This combination uses acetaminophen to reduce pain and fever via COX inhibition, and dexmedetomidine to provide sedation and analgesia through alpha-2 adrenergic receptor agonism. Used for Perioperative analgesia and sedation, Sedation in intensive care unit patients.

At a glance

Generic nameIV acetaminophen & IV dexmedetomidine
Also known asOfirmev, Precedex
SponsorBeth Israel Deaconess Medical Center
Drug classAnalgesic/sedative combination
TargetCOX enzymes (acetaminophen); alpha-2 adrenergic receptors (dexmedetomidine)
ModalitySmall molecule
Therapeutic areaAnesthesia/Critical Care
PhaseFDA-approved

Mechanism of action

Acetaminophen inhibits cyclooxygenase enzymes to reduce prostaglandin synthesis, lowering pain and fever perception. Dexmedetomidine is a selective alpha-2 adrenergic agonist that produces sedation, analgesia, and anxiolysis by activating presynaptic and postsynaptic alpha-2 receptors in the central nervous system. Together, they provide multimodal analgesia and sedation for perioperative or critical care settings.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: